The nanopore ability to generate long-reads was also exploited to characterize the BCR-ABL1 genomic breakpoint in ten patients affected by CML, in order to develop an approach for the “personalized monitoring” of residual disease during follow-up (Cumbo et al., 2018). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.